Abraham W.T., Fisher W.G., Smith A.L. et al. Cardiac resynchronization in chronic heart failure // N. Engl. J. Med. - 2002. - Vol. 346. - P. 1845-1853.
Crilley J.G., Boehm E.A., Blair E. et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1776-1782.
Drazner M.H., Rame J.E., Stevenson L.W. et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure // N. Engl. J. Med. - 2001. - Vol. 345. - P. 574-581.
Elkayam U., Tummala P.P., Rao K. et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy // N. Engl. J. Med. - 2001. - Vol. 344. - P. 1567-1571.
Eshtehardi P., Koestner S., Adorjan P. et al. Transient apical ballooning syndrome - clinical characteristics, ballooning pattern, and long-term follow-up in a Swiss population // Int. J. Cardiol. - 2008, Jul 1. - Epub ahead of print.
Faber L., Meissner A., Ziemssen P. et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow-up of the first series of 25 patients // Heart. -
- Vol. 83. - P. 326-331.
Hess O.M., Sigwart U. New treatment strategies for hypertrophic obstructive cardiomyopathy // Alcohol ablation of the septum: the new gold standard? // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 2054-2055.
Jenni R., Oechslin E., Schneider J. et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy // Heart. - 2001. - Vol. 86. - P. 666-671.
Kuhl, U., Pauschinger, M amp; Noutsias, M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with ‘idiopathic’ left ventricular dysfunction // Circulation. - 2005. - Vol. 111. - P. 887-893.
Maron B.J., McKenna W.J., Danielson G.K. et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy // Eur. Heart J. - 2003. - Vol. 24. - P. 1965-1991.
McCarthy R.E., Boehmer J.P., Hruban R.H. et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis // N. Engl. J. Med. - 2000. - Vol. 342. - P. 690-695.
Piano M.R. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology // Chest. -
- Vol. 121. - P. 1638-1650.
Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease // N. Engl. J. Med. - 2004. - Vol. 350. - P. 2383-2397.
Skinner M., Sanchorawala V., Seldin DC et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study // Ann. Intern. Med. - 2004. - Vol. 140. - P. 85-93.
Thiene G., Nava, A., Corrado D. et al. Right ventricular cardiomyopathy and sudden death in young people // N. Engl. J. Med. - 1988. - Vol. 318. - P. 129-133.
Towbin J.A., Bowles N.E. The failing heart // Nature. - 2002. - Vol. 415. - P. 227-233.
СПИСОК ЛИТЕРАТУРЫ
Geisterfer-Lowrance              A.A., Kass S., Tanigawa G. et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation // Cell. - 1990. - Vol. 62. - P. 999-1006.
Watkins              H., McKenna W.J., Thierfelder L. et al. Mutations in the genes for cardiac troponin T and alpha- tropomyosin in hypertrophic cardiomyopathy // N. Engl. J. Med. - 1995. - Vol. 332. - P. 1058-1064.
Charron              P., Carrier L., Dubourg O. et al. Penetrance of familial hypertrophic cardiomyopathy // Genet. Couns. - 1997. - Vol. 8. - P. 107-114.
4.Sachdev B., Takenaka T., Teraguchi H. et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy // Circulation. - 2002. - Vol. 105. - P. 1407-1411.
Charron              P., Villard E., Sebillon P. et al. Danon’s disease as a cause of hypertrophic cardiomyopathy: a systematic survey // Heart. - 2004. - Vol. 90. - P. 842-846.
Marian              A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy // Lancet. - 2000. - Vol. 355. - P. 58-60.
Lankford              E.B., Epstein N.D., Fananapazir L. et al. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy //
J. Clin. Invest. - 1995. - Vol. 95. - P. 1409-1414.
Watkins              H., Seidman C.E., Seidman J.G. et al. Expression and functional assessment of a truncated cardiac troponin T that causes hypertrophic cardiomyopathy. Evidence for a dominant negative action //
J. Clin. Invest. - 1996. - Vol. 98. - P. 2456-2461.
Lowey              S. Functional consequences of mutations in the myosin heavy chain at sites implicated in familial hypertrophic cardiomyopathy // Trends Cardiovasc. Med. - 2002. - Vol. 12. - P. 348-354.
Lin              D., Bobkova A., Homsher E. et al. Altered cardiac troponin T in vitro function in the presence of a mutation implicated in familial hypertrophic cardiomyopathy // J. Clin. Invest. - 1996. - Vol. 97. - P. 28422848.
11 .Sweeney H.L., Feng H.S., Yang Z. et al. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function // Proc. Natl.
Acad. Sci. USA. - 1998. - Vol. 95. - P. 14406-14410.
Michele              D.E., Albayya F.P., Metzger J.M. Direct, convergent hypersensitivity of calcium-activated force generation produced by hypertrophic cardiomyopathy mutant alpha-tropomyosins in adult cardiac myocytes // Nat. Med. - 1999. - Vol. 5. - P. 1413-1417.
Ashrafian              H., Redwood C., Blair E. et al. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion // T rends Genet. - 2003. - Vol. 19. - P. 263-268.
Ristow              M., Pfister M.F., Yee A.J. et al. Frataxin activates mitochondrial energy conversion and oxidative phosphorylation // Proc. Natl. Acad. Sci. USA. - 2000. - Vol. 97. - P. 12239-12243.
Blair              E., Redwood C., Ashrafian H. et al. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis // Hum. Mol. Genet. - 2001. - Vol. 10. - P. 1215-1220.
Lucke              T., Hoppner W., Schmidt E. et al. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts // Mol. Genet. Metab. - 2004. - Vol. 82. - P. 93-97.
Crilley              J.G., Boehm E.A., Blair E. et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1776-1782.
Krams              R., Kofflard M.J., Duncker D.J. et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation // Circulation. - 1998. - Vol. 97. - P. 230-233.
Krams              R., Ten Cate F.J., Carlier S.G. et al. Diastolic coronary vascular reserve: a new index to detect changes in the coronary microcirculation in hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. - 2004. - Vol. 43. - P. 670-677.
Levine              R.A., Vlahakes G.J., Lefebvre X. et al. Papillary muscle displacement causes systolic anterior motion of the mitral valve. Experimental validation and insights into the mechanism of subaortic obstruction // Circulation. - 1995. - Vol. 91. - P. 1189-1195.
21 .Sherrid M.V., Gunsburg D.Z., Moldenhauer S. et al. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy // J. Am. Coll. Cardiol. -
- Vol. 36. - P. 1344-1354.
Lim P.O., Morris-Thurgood J.A., Frenneaux M.P. Vascular mechanisms of sudden death in hypertrophic cardiomyopathy, including blood pressure responses to exercise // Cardiol. Rev. - 2002. - Vol. 10. - P. 15-23.
23.Spirito P., Maron B.J., Bonow R.O. et al. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy // Am. J. Cardiol. - 1987. - Vol. 60. - P. 123-129.
Thaman              R., Gimeno J.R., Reith S. et al. Progressive left ventricular remodeling in patients with hypertrophic cardiomyopathy and severe left ventricular hypertrophy // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 398-405.
Maron              B.J., McKenna W.J., Danielson G.K. et al. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines // J. Am. Coll. Cardiol. - 2003. - Vol. 42. - P. 1687-1713.
McKenna              W.J., Spirito P., Desnos M. et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families // Heart. -
- Vol. 77. - P. 130-132.
Wigle              E.D., Rakowski H., Kimball B.P. et al. Hypertrophic cardiomyopathy: clinical spectrum and treatment // Circulation. - 1995. - Vol. 92. - P. 1680-1692.
Maron              B.J. Hypertrophic cardiomyopathy: a systematic review // JAMA. - 2002. - Vol. 287. - P. 13081320.
29.Spirito P., Maron B.J. Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy // J. Am. Coll. Cardiol. - 1999. - Vol. 33. - P. 1071-1075.
Hess              O.M., Sigwart U. New treatment strategies for hypertrophic obstructive cardiomyopathy. Alcohol ablation of the septum: the new gold standard? // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 2054-2055.
Maron              B.J., Shen W.K., Link M.S. et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy // N. Engl. J. Med. - 2000. - Vol. 342. - P. 365-373.
32.Seiler Ch., Hess O.M., Schoenbeck M. et al. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study // J. Am. Coll. Cardiol. - 1991. - Vol. 17. - P. 634642.
33.Woo A., Williams W.G., Choi R. et al. Clinical and ecochardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy // Circulation. - 2005. - Vol. 111. - P. 2033-2041.
34.Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy // Lancet. - 1995. - Vol. 346. - P. 211-214.
35.Seggewiss H., Faber L., Ziemssen P. et al. [One-year follow-up after echocardiographically-guided percutaneous septal ablation in hypertrophic obstructive cardiomyopathy] // Dtsch. Med. Wochenschr. -
- Vol. 126. - P. 424-430.
36.Spirito P., Bellone P., Harris K.M. et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy // N. Engl. J. Med. - 2000. - Vol. 342. - P. 1778-1785.
Wilson W., Taubert K.A., Gewitz M. et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and
the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group // Circulation. - 2007. - Vol. 116. - P. 17361754.
Richardson              P., McKenna W., Bristow M. et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies // Circulation. - 1996. - Vol. 93. - P. 841-842.
Noutsias              M., Seeberg B., Schultheiss H.P. et al. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy // Circulation. -
- Vol. 99. - P. 2124-2131.
Dettmeyer              R., Reith K., Madea B. Alcoholic cardiomyopathy versus chronic myocarditis: immunohistological investigations with LCA, CD3, CD68 and tenascin // Forensic. Sci. Int. - 2002. - Vol. 126. - P. 57-62.
41 .Mahon N.G., Madden B.P., Caforio A.L. et al. Immunohistologic evidence of myocardial disease in apparently healthy relatives of patients with dilated cardiomyopathy // J. Am. Coll. Cardiol. - 2002. - Vol. 39. - P. 455-462.
Kuhl              U., Pauschinger M., Noutsias M. et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction // Circulation. - 2005. - Vol. 111. - P. 887-893.
Frustaci              A., Chimenti C., Ricci R. et al. Improvement in cardiac function in the cardiac variant of Fabry’s disease with galactose-infusion therapy // N. Engl. J. Med. - 2001. - Vol. 345. - P. 25-32.
Kuhl              U., Pauschinger M., Schwimmbeck P.L. et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction // Circulation. - 2003. - Vol. 107. - P. 2793-2798.
Frustaci              A., Chimenti C., Calabrese F. et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders // Circulation. - 2003. - Vol. 107. - P. 857-863.
Wojnicz              R., Nowalany-Kozielska E., Wojciechowska C. et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results // Circulation. - 2001. - Vol. 104. - P. 39-45.
Baig              M.K., Goldman J.H., Caforio A.L. et al. Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease // J. Am. Coll. Cardiol. - 1998. -
Vol. 31. - P. 195-201.
Mestroni              L., Maisch B., McKenna W.J. et al. Guidelines for the study of familial dilated cardiomyopathies. Collaborative Research Group of the European Human and Capital Mobility Project on Familial Dilated Cardiomyopathy // Eur. Heart J. - 1999. - Vol. 20. - P. 93-102.
Mason              J.W. Myocarditis and dilated cardiomyopathy: an inflammatory link // Cardiovasc. Res. - 2003. - Vol. 60. - P. 5-10.
Zhang              H., Li Y., McClean D.R. et al. Detection of enterovirus capsid protein VP1 in myocardium from cases of myocarditis or dilated cardiomyopathy by immunohistochemistry: further evidence of enterovirus persistence in myocytes // Med. Microbiol. Immunol. (Berl.). - 2004. - Vol. 193. - P. 109-114.
51 .Andreoletti L., Bourlet T., Moukassa D. et al. Enteroviruses can persist with or without active viral replication in cardiac tissue of patients with end-stage ischemic or dilated cardiomyopathy // J. Infect.
Dis. - 2000. - Vol. 182. - P. 1222-1227.
Caforio              A.L., Mahon N.J., Tona F. et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance // Eur. J. Heart Fail. - 2002. - Vol. 4. - P. 411-417.
Mahon              N.G., Zal B., Arno G. et al. Absence of viral nucleic acids in early and late dilated cardiomyopathy // Heart. - 2001. - Vol. 86. - P. 687-692.
Towbin              J.A., Bowles N.E. The failing heart // Nature. - 2002. - Vol. 415. - P. 227-233.
Hoffman              E.P., Brown R.H., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus // Cell. - 1987. - Vol. 51. - P. 919-928.
Lapidos              K.A., Kakkar R., McNally E.M. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma // Circ. Res. - 2004. - Vol. 94. - P. 1023-1031.
Mogensen              J., Klausen I.C., Pedersen A.K. et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy // J. Clin. Invest. - 1999. - Vol. 103. - P. 39-43.
58.Olson T.M., Kishimoto N.Y., Whitby F.G. et al. Mutations that alter the surface charge of alpha- tropomyosin are associated with dilated cardiomyopathy // J. Mol. Cell. Cardiol. - 2001. - Vol. 33. - P. 723732.
Bowles              N.E., Bowles K.R., Towbin J.A. The "final common pathway" hypothesis and inherited cardiovascular disease. The role of cytoskeletal proteins in dilated cardiomyopathy // Herz. - 2000. - Vol. 25. - P. 168-175.
Vatta              M., Mohapatra B., Jimenez S. et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction // J. Am. Coll. Cardiol. - 2003. - Vol. 42. - P. 20142027.
61 .Crispell K.A., Hanson E.L., Coates K. et al. Periodic rescreening is indicated for family members at risk of developing familial dilated cardiomyopathy // J. Am. Coll. Cardiol. - 2002. - Vol. 39. - P. 1503-1507.
Mogensen              J., Murphy R.T., Shaw T. et al. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 2033-2040.
Murphy              R.T., Mogensen J., Shaw A. et al. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy // Lancet. - 2004. - Vol. 363. - P. 371-372.
64.Schmitt J.P., Kamisago M., Asahi M. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban // Science. - 2003. - Vol. 299. - P. 1410-1413.
Lammerding              J., Schulze P.C., Takahashi T. et al. Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction // J. Clin. Invest. - 2004. - Vol. 113. - P. 370-378.
Vohanka              S., Vytopil M., Bednarik J. et al. A mutation in the X-linked Emery-Dreifuss muscular dystrophy gene in a patient affected with conduction cardiomyopathy // Neuromuscul. Disord. - 2001. - Vol. 11. - P. 411-413.
Vatta              M., Stetson S.J., Perez-Verdia A. et al. Molecular remodelling of dystrophin in patients with end- stage cardiomyopathies and reversal in patients on assistance-device therapy // Lancet. - 2002. -
Vol. 359. - P. 936-941.
Lenarda              A., Pinamonti B., Mestroni L. et al. The natural history of dilated cardiomyopathy: a review of the Heart Disease Registry of Trieste // Ital. Heart J. Suppl. - 2004. - Vol. 5. - P. 253-266.
Michels              V.V., Driscoll D.J., Miller F.A. et al. Progression of familial and non-familial dilated cardiomyopathy: a long term follow-up // Heart. - 2003. - Vol. 89. - P. 757-761.
Cicoira              M., Zanolla L., Latina L. et al. Frequency, prognosis and predictors of improvement of left ventricular function in patients with classical clinical diagnosis of idiopathic dilated cardiomyopathy // Eur. J. Heart Fail. - 2001. - Vol. 3. - P. 323-330.
Bahler              R.C. Assessment of prognosis in idiopathic dilated cardiomyopathy // Chest. - 2002. - Vol. 121. - P. 1016-1019.
McKee              P.A., Castelli W.P., McNamara P.M. et al. The natural history of congestive heart failure: the Framingham study // N. Engl. J. Med. - 1971. - Vol. 285. - P. 1441-1446.
Drazner              M.H., Rame J.E., Stevenson L.W. et al. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure // N. Engl. J. Med. - 2001. - Vol. 345. - P. 574-581.
Remondino              A., Kwon S.H., Communal C. et al. p-Adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway // Circ. Res. - 2003. - Vol. 92. - P. 136-138.
Leri              A., Claudio P.P., Li Q. et al. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell // J. Clin. Invest. - 1998. - Vol. 101. - P. 1326-1342.
76.Ing D.J., Zang J., Dzau V.J. et al. Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x // Circ. Res. - 1999. - Vol. 84. - P. 21-33.
Rockman              H.A., Chein K.R., Choi D.J. et al. Expression of beta adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice // Proc. Natl. Acad. Sci. USA. - 1998. - Vol. 95. - P. 7000-7005.
Bristow              M.R., O'Connell G.P., Gilbert E.M. et al. Dose-response of chronic p-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy // Circulation. - 1994. - Vol. 89. - P. 28072816.
79.Schmidt A.G., Edes I., Kranias E.G. Phospholamban: a promising new therapeutic target in heart failure? // Cardiovasc. Drugs Ther. - 2001. - Vol. 15. - P. 387-396.
80.Song Q., Schmidt A.G., Hahn H.S. et al. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy // J. Clin. Invest. - 2003. - Vol. 111. - P. 859-867.
McFarlane              S.I., Winer N., Sowers J.R. et al. Role of the natriuretic peptide system in cardiorenal protection // Arch. Intern. Med. - 2003. - Vol. 163. - P. 2696-2704.
Leinwand              L.A. Sex is potent modifier of the cardiovascular system //
J. Clin. Invest. - 2003. - Vol. 112. - P. 302-307.
Lemos              L.A., McGuire D.K., Drazner M.H. B-natriuretic peptide in cardiovascular disease // Lancet. -
- Vol. 362. - P. 316-322.
Throughton              R.W., Frampton C.M., Yandle T.G. et al. Treatment of heart failure by plasma aminoterminal brain-natriuretic peptide (N-BNP) concentrations // Lancet. - 2000. - Vol. 355. - P. 11121113.
Tsutamoto              T., Hisanaga T., Wada A. et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with CHF // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 391-398.
Vrtovec              B., Delgado R., Zewail A. et al. Prolonged QTc interval and B-natriuretic peptide levels together predict mortality in patients with advanced heart failure // Circulation. - 2003. - Vol. 107. - P. 1764-1769.
Grunig              E., Benz A., Mereles D. et al. Prognostic value of serial cardiac assessment and familial screening in patients with dilated cardiomyopathy // Eur. J. Heart Fail. - 2003. - Vol. 5. - P. 55-62.
Romano              M.A., Bolling S.F. Update on mitral valve repair in dilated cardiomyopathy // J. Cardiovasc. Surg. (Torino). - 2004. - Vol. 19. - P. 396-400.
89.Stelken A.M., Younis L.T., Jennison S.H. et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy // J. Am. Coll. Cardiol. - 1996. - Vol. 27. - P. 345-352.
Gitt              A.K., Wasserman K., Kilkowski C. et al. Exercise anaerobic threshold and ventilatory efficiency identify heart failure patients for high risk of early death // Circulation. - 2002. - Vol. 106. - P. 3079-3084.
Al-Saadi              N., Nagel E., Gross M. et al. Non-invasive detection of myocardial ischemia from perfusion based on nuclear magnetic resonance // Circulation. - 2000. - Vol. 101. - P. 1379-1383.
Kim              R.J., Fieno D.S., Parrish T.B. et al. Relation of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function // Circulation. - 1999. - Vol. 100. - P. 1992-2000.
Hunt              S.A., Baker D.W., Chin M.H. et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult // Circulation. - 2001. - Vol. 104. - P. 2996-3007.
Young              J.B., Dunlap M.E., Pfeffer M.A. et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials // Circulation. - 2004. - Vol. 110. - P. 2618-2626.
Fauchier              L., Babuty D., Poret P. et al. Comparison of long-term outcome of alcoholic and idiopathic dilated cardiomyopathy // Eur. Heart J. - 2000. - Vol. 21. - P. 306-314.
Belardinelli              R., Georgiou D., Cianci G. et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome // Circulation. - 1999. - Vol. 99. - P. 1173-1182.
Cazeau              S., Leclercq C., Lavergne T. et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay // N. Engl. J. Med. - 2001. - Vol. 344. - P. 873-880.
Abraham              W.T., Fisher W.G., Smith A.L. et al. Cardiac resynchronization in chronic heart failure // N. Engl. J. Med. - 2002. - Vol. 346. - P. 1845-1853.
Bristow              M.R., Saxon L.A., Boehmer J. et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure // N. Engl. J. Med. - 2004. - Vol. 350. - P. 21402150.
100.0’Connell J.B., Breen T.J., Hosenpud J.D. Heart transplantation in dilated heart muscle disease and myocarditis // Eur. Heart J. - 1995. - Vol. 16. - P. 137-139.
Hetzer              R., Muller J.H., Weng Y.G. et al. Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy // J. Thorac. Cardiovasc. Surg. - 2000. - Vol. 120. - P. 843-853.
Yacoub              M.H. A novel strategy to maximize the efficacy of left ventricular assist devices as a bridge to recovery // Eur. Heart J. - 2001. - Vol. 22. - P. 534-540.
Birks              E.J., Yacoub M.H., Banner N.R. et al. The role of bridge to transplantation: should LVAD patients be transplanted? // Curr. Opin. Cardiol. - 2004. - Vol. 19. - P. 148-153.
Franco-Cereceda              A., McCarthy P.M., Blackstone E.H. et al. Partial left ventriculectomy for dilated cardiomyopathy: is this an alternative to transplantation? // J. Thorac. Cardiovasc. Surg. - 2001. - Vol. 121. - P. 879-893.
Grimm              W., Hoffmann J., Menz V. et al. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia //
J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 739-745.
Fruhwald              F.M., Eber B., Schumacher M. et al. Syncope in dilated cardiomyopathy is a predictor of sudden cardiac death // Cardiology. - 1996. - Vol. 87. - P. 177-180.
Grimm              W., Glaveris C., Hoffmann J. et al. Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour Holter electrocardiography // Am. Heart. J. - 2000. - Vol. 140. - P. 43-51.
Zecchin              M., Lenarda A., Proclemer A. et al. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy // Europace. - 2004. - Vol. 6. - P. 400-406.
Metoprolol              CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Effect of metoprolol CR/XL in chronic heart failure // Lancet. - 1999. - Vol. 353. - P. 2001-2007.
Pitt              B., Zannad F., Remme W.J. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure // N. Engl. J. Med. - 1999. - Vol. 341. - P. 709-717.
Hohnloser              S.H., Klingenheben T., Bloomfield D. et al. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 2220-2224.
112.Strickberger S.A., Hummel J.D., Bartlett T.G. et al. Amiodarone versus implantable cardioverter- defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 1707-1712.
113.Bardy G.H., Lee K.L., Mark D.B. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure // N. Engl. J. Med. - 2005. - Vol. 352. - P. 225-237.
114.Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. II. Echocardiographic features of patients at risk // Ann. Intern. Med. - 1992. - Vol. 116. - P. 612.
Dries              D.L., Rosenberg Y.D., Waclawiw M.A. et al. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials // J. Am. Coll. Cardiol. - 1997. - Vol. 29. - P. 1074-1080.
Diet              F., Erdmann E. Thromboembolism in heart failure: who should be treated? // Eur. J. Heart Fail. -
- Vol. 2. - P. 355-363.
Koniaris              L.S., Goldhaber S.Z. Anticoagulation in dilated cardiomyopathy // J. Am. Coll. Cardiol. -
- Vol. 31. - P. 745-748.
Massie              B.M., Collins J.F., Ammon S.E. et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Theraphy in Chronic Heart Failure (WATCH) trial // Circulation. - 2009. - Vol. 119. - P. 1616-1624.
Crispell              K.A., Wray A., Ni H. et al. Clinical profiles of four large pedigrees with familial dilated cardiomyopathy: preliminary recommendations for clinical practice // J. Am. Coll. Cardiol. - 1999. - Vol. 34. - P. 837-847.
120.Sugrue D.D., Rodeheffer R.J., Codd M.B. et al. The clinical course of idiopathic dilated cardiomyopathy. A population-based study // Ann. Intern. Med. - 1992. - Vol. 117. - P. 117-123.
Bansch D., Antz M., Boczor S. et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT) // Circulation. - 2002. - Vol. 105. - P. 1453-1458.
McCarthy R.E., Boehmer J.P., Hruban R.H. et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis // N. Engl. J. Med. - 2000. - Vol. 342. - P. 690-695.
123.Steimle A.E., Stevenson L.W., Fonarow G.C. et al. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation // J. Am. Coll. Cardiol. - 1994. - Vol. 23. - P. 553559.
124.Dec G.W., Palacios I.F., Fallon J.T. et al. Active myocarditis in the spectrum of acute dilated cardiomyopathies. Clinical features, histologic correlates, and clinical outcome // N. Engl. J. Med. - 1985. - Vol. 312. - P. 885-890.
125.Schaufelberger M., Swedberg K., Koster M. et al. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden: data from the Swedish Hospital Discharge Registry 1988 to 2000 // Eur. Heart J. - 2004. - Vol. 25. - P. 300-307.
Why              H.J., Meany B.T., Richardson P.J. et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy // Circulation. -
- Vol. 89. - P. 2582-2589.
Fujioka              S., Kitaura Y., Ukimura A. et al. Evaluation of viral infection in the myocardium of patients with idiopathic dilated cardiomyopathy // J. Am. Coll. Cardiol. - 2000. - Vol. 36. - P. 1920-1926.
Kanzaki              Y., Terasaki F., Okabe M. et al. Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy // Jpn Circ. J. - 2001. - Vol. 65. - P. 797-802.
Limas              C.J., Hasikidis C., Iakovou J. et al. Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy // Eur. J. Clin. Invest. - 2003. - Vol. 33. - P. 443-448.
Grimm              W., Rudolph S., Christ M. et al. Prognostic significance of morphometric endomyocardial biopsy analysis in patients with idiopathic dilated cardiomyopathy // Am. Heart J. - 2003. - Vol. 146. - P. 372-376.
Grogan              M., Redfield M.M., Bailey K.R. et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy // J. Am. Coll. Cardiol. - 1995. - Vol. 26. - P. 80-84.
Taylor              M.R., Fain P.R., Sinagra G. et al. Natural history of dilated cardiomyopathy due to lamin A/C gene mutations // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 771-780.
Davies              J.N.P. Endomyocardial necrosis. A heart disease of obscure aetiology in Africa. MD thesis. - Bristol, 1948.
134.Shaper A.G., Hutt M.S.R., Coles R.M. Necropsy study of endomyocardial fibrosis and rheumatic heart disease in Uganda 1960-1965 // Br. Heart J. - 1968. - Vol. 30. - P. 391-401.
135.Somers K., Hutt M.S.R., Patel A.K. et al. Endomyocardial biopsy in diagnosis of cardiomyopathies // Br. Heart J. - 1971. - Vol. 33. - P. 822-832.
Chew              C.Y.C., Ziady G.M., Raphael M.J. et al. Primary restrictive cardiomyopathy. Nontropical endomyocardial fibrosis and hypereosinophilic heart disease // Br. Heart J. - 1977. - Vol. 39. - P. 399-413.
Hess              O.M. Endomyokardfibrose. - Stuttgart: Thieme Verlag, 1981. - P. 4717-4721.
Brockington              J.F., Olsen E.G.J. Loffler’s endocarditis and Davies’ endomyocardial fibrosis // Am. Heart J. - 1973. - Vol. 85. - P. 308-322.
139.Spry Ch.J.F. The pathogenesis of endomyocardial fibrosis: the role of the eosinophil // Springer Semin. Immunopathol. - 1989. - Vol. 11. - P. 471-477.
Venge              P. The human eosinophil in inflammation // Agents Actions. - 1990. - Vol. 12. - P. 123-126.
Loffler              W. Endocarditis parietalis fibroplastica mit Bluteosinophilie // Schweiz. Med. Wochenschr. - 1936. - Vol. 66. - P. 817-820.
Thuring              Ch., Hess O.M., Murakami T. et al. Normalwerte der linksventrikularen Funktion. Biplane Angiokardiographie, unter Berucksichtigung geschlechtsspezifischer Unterschiede // Fortschr.
Rontgenstr. - 1989. - Vol. 150. - P. 562-568.
Roelandt              J.R.T.C., Sutherland G.P., Iliceto S. et al // Cardiac. Ultrasound. - Edinburgh: Churchill Livingstone, 1993.
Braunwald              E. Heart Disease. - Philadelphia: Elsevier-Saun-ders, 2005. - 1689 p.
Liesveld              J.L., Abboud C.N. State of the art: the hypereosinophilic syndromes // Blood Rev. - 1991. - Vol. 5. - P. 29-37.
Ackermann              S.J., Butterfield H. Eosinophilia, eosinophil-associated diaeases, chronic eosinophil leukaemia, and the hypereosinophilic syndromes. - Hematology: Basic Principles and Practice, 2005. Philadelphia. - P. 763-786.
Weller              P.F., Glenn B.J. The idiopathic hypereosinophilic syndrome // Blood. - 1994. - Vol. 10. - P. 2759-2771.
Dubost              Ch., Maurice P., Gerbaux A. et al. The surgical treatment of constrictive fibrous endocarditis // Ann. Surg. - 1976. - Vol. 184. - P. 303-307.
Cherian              G., Vijayaraghavan G., Krishnaswami S. et al. Endomyocardial fibrosis: report on the hemodynamic data in 29 patients and review of the results of surgery // Am. Heart J. - 1983. - Vol. 4. - P. 659-665.
Hess              O.M., Turina M., Senning A. et al. Pre- and postoperative findings in patients with endomyocardial fibrosis // Br. Heart J. - 1978. - Vol. 40. - P. 406-415.
Metras              D., Coulibaly A.Q., Quattara K. et al. Endomyocardial fibrosis: early and late results of surgery in 20 patients // J. Thorac. Cardiovasc. Surg. - 1982. - Vol. 83. - P. 52-64.
Moraes              C.R., Buffolo E.L., Lima R. et al. Surgical treatment of endomyocardial fibrosis // J. Thorac. Cardiovasc. Surg. - 1983. - Vol. 85. - P. 738-745.
Blakrishnan              K.G., Venkitachalam C.G., Pillai V.R.K. et al. Post-operative evaluation of endomyocardial fibrosis // Cardiology. - 1986. - Vol. 73. - P. 73-84.
Davies              J., Sapsford R., Brooksby I. et al. Successful surgical treatment of two patients with eosinophilic endomyocardial disease // Br. Heart J. - 1981. - Vol. 46. - P. 438-445.
Hess              O.M., Turina M., Egloff L. et al. Velauf der Endomyokardfibrose nach chirurgischer Endokarddekortikation // Schweiz. Med. Wochenschr. - 1984. - Vol. 114. - P. 1595-1598.
156.Schneider U., Jenni R., Turina J. et al. Long-term follow up of patients with endomyocardial fibrosis: effects of surgery // Heart. - 1998. - Vol. 79. - P. 362-367.
Tanaka              F., Migita K., Honda S. et al. Clinical outcome and survival of secondary (AA) amyloidosis // Clin. Exp. Rheumatol. - 2003. - Vol. 21. - P. 343-346.
Rahman              J.E., Helou E.F., Gelzer-Bell R. et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis // J. Am. Coll. Cardiol. - 2004. - Vol. 43. - P. 410-415.
159.Skinner M., Sanchorawala V., Seldin D.C. et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study // Ann. Intern. Med. - 2004. - Vol. 140. - P. 85-93.
Kyle              R.A., Spittell P.C., Gertz M.A. et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement // Am. J. Med. - 1996. - Vol. 101. - P. 395-400.
Rybicki              B.A., Iannuzzi M.C., Frederick M.M. et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS) // Am. J. Respir. Crit. Care Med. - 2001. - Vol. 164. - P. 20852091.
162.Silverman K.J., Hutchins G.M., Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis // Circulation. - 1978. - Vol. 58. - P. 1204-1211.
Matsui              Y., Iwai K., Tachibana T. et al. Clinicopathological study of fatal myocardial sarcoidosis // Ann. N.Y. Acad. Sci. - 1976. - Vol. 278. - P. 455-469.
Bargout              R., Kelly R.F. Sarcoid heart disease: clinical course and treatment // Int. J. Cardiol. - 2004. - Vol. 97. - P. 173-182.
Fahy              G.J., Marwick T., McCreery C.J. et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis // Chest. - 1996. - Vol. 109. - P. 62-66.
Haywood              L.J., Sharma O.P., Siegel M.E. et al. Detection of myocardial sarcoidosis by thallium 201 imaging // J. Natl. Med. Assoc. - 1982. - Vol. 74. - P. 959-964.
Furushima              H., Chinushi M., Sugiura H. et al. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome // Clin. Cardiol. - 2004. - Vol. 27. - P. 217-222.
168.Ott P., Marcus F.I., Sobonya R.E. et al. Cardiac sarcoidosis masquerading as right ventricular dysplasia // Pacing. Clin. Electrophysiol. - 2003. - Vol. 26. - P. 1498-1503.
Umetani              K., Ishihara T., Yamamoto K. et al. Successfully treated complete atrioventricular block with corticosteroid in a patient with cardiac sarcoidosis: usefulness of gallium-67 and thallium-201 scintigraphy // Intern. Med. - 2000. - Vol. 39. - P. 245-248.
Takada              K., Ina Y., Yamamoto M. et al. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy // Sarcoidosis. - 1994. - Vol. 11. - P. 113-117.
Pietrangelo              A. Hereditary hemochromatosis: a new look at an old disease // N. Engl. J. Med. - 2004. - Vol. 350. - P. 2383-2397.
172.Olson L.J., Edwards W.D., McCall J.T. et al. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy // J. Am. Coll. Cardiol. - 1987. - Vol. 10. - P. 1239-1243.
173.Eaton J.W., Qian M. Molecular bases of cellular iron toxicity // Free Radic. Biol. Med. - 2002. - Vol. 32. - P. 833-840.
174.Short E.M., Winkle R.A., Billingham M.E. Myocardial involvement in idiopathic hemochromatosis. Morphologic and clinical improvement following venesection // Am. J. Med. - 1981. - Vol. 70. - P. 12751279.
Yalcinkaya              S., Kumbasar S.D., Semiz E. et al. Sustained ventricular tachycardia in cardiac hemochromatosis treated with amiodarone //
J. Electrocardiol. - 1997. - Vol. 30. - P. 147-149.
Anderson              L.J., Holden S., Davis B. et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload // Eur. Heart J. - 2001. - Vol. 22. - P. 2171-2179.
Westra              W.H., Hruban R.H., Baughman K.L. et al. Progressive hemochromatotic cardiomyopathy despite reversal of iron deposition after liver transplantation // Am. J. Clin. Pathol. - 1993. - Vol. 99. - P. 39-44.
Gilbert-Barness              E. Metabolic cardiomyopathy and conduction system defects in children // Ann. Clin. Lab. Sci. - 2004. - Vol. 34. - P. 15-34.
Kishnani              P.S., Howell R.R. Pompe disease in infants and children //
J. Pediatr. - 2004. - Vol. 144. - Vol. 5. - P. 35-43.
Guertl              B., Noehammer C., Hoefler G. Metabolic cardiomyopathies // Int. J.              Exp.              Pathol.              -              2000.              -
Vol. 81. - P. 349-372.
Den              Hout H., Reuser A.J., Vulto A.G. et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients // Lancet. - 2000. - Vol. 356. - P. 397-398.
Amalfitano              A., Bengur A.R., Morse R.P. et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial // Genet. Med. -
- Vol. 3. - P. 132-138.
Bosone              I., Vercelli L., Mongini T. et al. Glycogen storage disease type              II diagnosed in              a              74-year-old
woman // J. Am. Geriatr. Soc. - 2004. - Vol. 52. - P. 1034-1035.
Wolfsdorf              J.I., Weinstein D.A. Glycogen storage diseases // Rev. Endocr. Metab. Disord. - 2003. - Vol. 4. - P. 95-102.
Cuspidi              C., Sampieri L., Pelizzoli S. et al. Obstructive hypertrophic cardiomyopathy in type III glycogen-storage disease // Acta. Cardiol. - 1997. - Vol. 52. - P. 117-123.
Moses              S.W., Parvari R. The variable presentations of glycogen storage disease type              IV: a              review              of
clinical, enzymatic and molecular studies // Curr. Mol. Med. - 2002. - Vol. 2. - P. 177-188.
McConkie-Rosell              A., Wilson C., Piccoli D.A. et al. Clinical and laboratory findings in four patients with the non-progressive hepatic form of type IV glycogen storage disease // J. Inherit. Metab. Dis. - 1996. - Vol. 19. - P. 51-58.
Nase              S., Kunze K.P., Sigmund M. et al. A new variant of type IV glycogenosis with primary cardiac manifestation and complete branching enzyme deficiency. In vivo detection by heart muscle biopsy // Eur. Heart J. - 1995. - Vol. 16. - P. 1698-1704.
Desnick              R.J., Brady R., Barranger J. et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy // Ann. Intern. Med. - 2003. - Vol. 138. - P. 338-346.
MacDermot              K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females // J. Med. Genet. - 2001. - Vol. 38. - P. 769775.
Linhart              A., Palecek T., Bultas J. et al. New insights in cardiac structural changes in patients with Fabry’s disease // Am. Heart J. - 2000. - Vol. 139. - P. 1101-1108.
Chimenti              C., Pieroni M., Morgante E. et al. Prevalence of Fabry disease in female patients with late- onset hypertrophic cardiomyopathy // Circulation. - 2004. - Vol. 110. - P. 1047-1053.
Adams              M.J., Hardenbergh P.H., Constine L.S. et al. Radiation-associated cardiovascular disease // Crit. Rev. Oncol. Hematol. - 2003. - Vol. 45. - P. 55-75.
King              V., Constine L.S., Clark D. et al. Symptomatic coronary artery disease after mantle irradiation for Hodgkin’s disease // Int. J. Radiat. Oncol. Biol. Phys. - 1996. - Vol. 36. - P. 881-889.
Byrd              B.F., Mendes L.A. Cardiac complications of mediastinal radiotherapy. The other side of the coin // J. Am. Coll. Cardiol. - 2003. - Vol. 42. - P. 750-751.
Thiene              G., Nava A., Corrado D. et al. Right ventricular cardiomyopathy              and sudden              death              in young
people // N. Engl. J. Med. - 1988. - Vol. 318. - P. 129-133.
Nava              A., Bauce B., Basso C. et al. Clinical profile and              long-term follow-up              of 37              families              with
arrhythmogenic right ventricular cardiomyopathy // J. Am. Coll. Cardiol. - 2000. - Vol. 36. - P. 2226-2233.
Corrado              D., Fontaine G., Marcus F.I. et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry // Circulation. - 2000. - Vol. 101. - P. 101
106.
Fontaine              G., Fontaliran F., Frank R. et al. [Arrhythmogenic right ventricular dysplasia. A new clinical entity] // Bull. Acad. Natl. Med. - 1993. - Vol. 177. - P. 501-514.
Fontaine              G., Fontaliran F., Hebert J.L. et al. Arrhythmogenic right ventricular dysplasia // Annu. Rev. Med. - 1999. - Vol. 50. - P. 17-35.
Fontaine              G., Chemla D., Fornes P. Arrhythmic right ventricular cardiomyopathy // Am. J. Cardiol. -
- Vol. 86. - P. 483-484.
Basso              C., Thiene G., Corrado D. et al. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? // Circulation. - 1996. - Vol. 94. - P. 983-991.
Basso              C., Calabrese F., Corrado D. et al. Postmortem diagnosis in sudden cardiac death victims: macroscopic, microscopic and molecular findings // Cardiovasc. Res. - 2001. - Vol. 50. - P. 290-300.
Corrado              D., Basso C., Thiene G. et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study // J. Am. Coll. Cardiol. - 1997. - Vol. 30. - P. 1512-1520.
Mallat              Z., Tedgui A., Fontaliran F. et al. Evidence of apoptosis in arrhythmogenic right ventricular dysplasia // N. Engl. J. Med. - 1996. - Vol. 335. - P. 1190-1196.
Thiene              G., Corrado D., Nava A. et al. Right ventricular cardiomyopathy:              is              there evidence              of an
inflammatory aetiology? // Eur. Heart J. - 1991. - Vol. 12. - P. 22-25.
Bowles              N.E., Ni J., Marcus F. et al. The detection of cardiotropic viruses in the              myocardium of
patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy // J. Am. Coll. Cardiol. - 2002. - Vol. 39. - P. 892-895.
Rampazzo              A., Nava A., Danieli G.A. et al. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24 // Hum. Mol. Genet. - 1994. - Vol. 3. - P. 959-962.
Paoloni              P., Cardinali L., Mennecozzi M. et al. [Arrhythmogenic right ventricular dysplasia. Report of a familial case] // Minerva Cardioangiol. - 1995. - Vol. 43. - P. 231-235.
210.Sabel K.G., Blomstrom-Lundqvist C., Olsson S.B et al. Arrhythmogenic right ventricular dysplasia in brother and sister: is it related to myocarditis? // Pediatr. Cardiol. - 1990. - Vol. 11. - P. 113-116.
Corrado              D., Thiene G. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: is there a single gold standard test? // J. Cardiovasc. Electrophysiol. - 2004. - Vol. 15. - P. 307-309.
Paul              M., Schulz-Bahr E., Breithard G. et al. Genetics of arrhythmogenic right ventricular cardiomyopathy: status quo and future perspectives // Z. Kardiol. - 2003. - Vol. 92. - P. 128-136.
Coonar              A.S., Protonotarios N., Tsatsopoulou A. et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21 // Circulation. - 1998. - Vol. 97. - P. 2049-2058.
Norgett              E.E., Hatsell S.J., Carvajal-Huerta L. et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma // Hum. Mol. Genet. - 2000. - Vol. 9. - P. 2761-2766.
Pinamonti              B., Miani D., Sinagra G. et al. Familial right ventricular dysplasia with biventricular involvement and inflammatory infiltration // Heart. - 1996. - Vol. 76. - P. 66-69.
Valente              M., Calabrese F., Thiene G. et al. In vivo evidence of apoptosis in arrhythmogenic right ventricular cardiomyopathy // Am. J. Pathol. - 1998. - Vol. 152. - P. 479-484.
McKenna              W.J., Thiene G., Nava A. et al. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy // Br. Heart J. - 1994. - Vol. 71. - P. 215-218.
Corrado              D., Fontaine G., Marcus F.I. et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry //
J. Cardiovasc. Electrophysiol. - 2000. - Vol. 11. - P. 827-832.
Rampazzo              A., Nava A., Erne P. et al. A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43 // Hum. Mol. Genet. - 1995. - Vol. 4. - P. 21512154.
220.Severini G.M., Krajinovic M., Pinamonti B. et al. A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14 // Genomics. - 1996. - Vol. 31. - P. 193-200.
Rampazzo              A., Nava A., Miorin M. et al. ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm // Genomics. - 1997. - Vol. 45. - P. 259-263.
Ahmad              F., Li D., Karibe A. et al. Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23 // Circulation. - 1998. - Vol. 98. - P. 2791-2795.
Melberg              A., Oldfors A., Blomstrom-Lundqvist C. et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q // Ann. Neurol. - 1999. -
Vol. 46. - P. 684-692.
Li              D., Ahmad F., Gardner M.J. et al. The locus of a novel gene responsible for arrhythmogenic right- ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12-p14 // Am. J. Hum. Genet. - 2000. - Vol. 66. - P. 148-156.
Rampazzo              A., Nava A., Malacrida S. et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy // Am. J. Hum. Genet. - 2002. - Vol. 71. - P. 1200-1206.
Frances              R., Rodriguez Benitez A.M., Cohen D.R. Arrhythmo-genic right ventricular dysplasia and anterior polar cataract // Am. J. Med. Genet. - 1997. - Vol. 73. - P. 125-126.
227.227. Jenni R., Oechslin E., Schneider J. et al. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy // Heart. - 2001. - Vol. 86. - P. 666-671.
Chin              T.K., Perloff J.K., Williams R.G. et al. Isolated noncompaction of left ventricular myocardium. A study of eight cases // Circulation. - 1990. - Vol. 82. - P. 507-513.
Boyd              M.T., Seward J.B., Tajik A.J. et al. Frequency and location of prominent left ventricular trabeculations at autopsy in 474 normal human hearts: implications for evaluation of mural thrombi by two-dimensional echocardiography // J. Am. Coll. Cardiol. - 1987. - Vol. 9. - P. 323-326.
Chung              T., Yiannikas J., Lee L.C. et al. Isolated noncompaction involving the left ventricular apex in adults // Am. J. Cardiol. - 2004. - Vol. 94. - P. 1214-1216.
Weiford              B.C., Subbarao V.D., Mulhern K.M. Noncompaction of the ventricular myocardium // Circulation. - 2004. - Vol. 109. - P. 2965-2971.
Lauer              R.M., Fink H.P., Petry E.L. et al. Angiographic demonstration of intramyocardial sinusoids in pulmonary-valve atresia with intact ventricular septum and hypoplastic right ventricle // N. Engl. J. Med. - 1964. - Vol. 271. - P. 68-72.
233.Ichida F., Tsubata S., Bowles K.R. et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome // Circulation. - 2001. - Vol. 103. - P. 1256-1263.
234.Bione S, D’Adamo P., Maestrini E. et al. A novel X-linked gene, G4.5 is responsible for Barth syndrome // Nat. Genet. - 1996. - Vol. 12. - P. 385-389.
235.Oechslin E.N., Attenhofer Jost C.H., Rojas J.R. et al. Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis // J. Am. Coll. Cardiol. -
- Vol. 36. - P. 493-500.
Junga              G., Kneifel S., Smekal A. et al. Myocardial ischaemia in children with isolated ventricular noncompaction // Eur. Heart J. - 1999. - Vol. 20. - P. 910-916.
Pignatelli              R.H., McMahon C.J., Dreyer W.J. et al. Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy // Circulation. - 2003. - Vol. 108. - P. 2672-2678.
238.Ichida F., Hamamichi Y., Miyawaki T. et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background // J. Am. Coll. Cardiol. - 1999. - Vol. 34. - P. 233-240.
239.Sasse-Klaassen S., Gerull B., Oechslin E. et al. Isolated noncompaction of the left ventricular myocardium in the adult is an autosomal dominant disorder in the majority of patients // Am. J. Med. Genet. - 2003. - Vol. 119. - P. 162-167.
Carlquist              J.F., Menlove R.L., Murray M.B. et al. HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Validation study and meta-analysis of published HLA association studies // Circulation. - 1991. - Vol. 83. - P. 515-522.
Kuhl              U., Pauschinger M., Bock T. et al. Parvovirus B19 infection mimicking acute myocardial infarction // Circulation. - 2003. - Vol. 108. - P. 945-950.
Noutsias              M., Fechner H., Jonge H. et al. Human coxsackie-adenovirus receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections // Circulation. - 2001. - Vol. 104. - P. 275-280.
Badorff              C., Lee G.H., Lamphear B.J. et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy // Nat. Med. - 1999. - Vol. 5. - P. 320-326.
Jahns              R., Boivin V., Hein L. et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy // J. Clin. Invest. - 2004. - Vol. 113. - P. 1419-1429.
245.Staudt A., Staudt Y., Dorr M. et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 829-836.
Li              J., Schwimmbeck P.L., Tschoepe C. et al. Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction // Cardiovasc Res. -
- Vol. 56. - P. 235-247.
Noutsias              M., Pauschinger M., Schultheiss H.P. et al. Cytotoxic perforin+ and TIA-1+ infiltrates are associated with cell adhesion molecule expression in dilated cardiomyopathy // Eur. J. Heart Fail. -
- Vol. 5. - P. 469-479.
Tschoepe              C., Bock C.T., Kasner M. et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction // Circulation. - 2005. - Vol. 111. - P. 879-886.
Noutsias              M., Pauschinger M., Poller W.C. et al. Immunomodulatory treatment strategies in inflammatory cardiomyopathy: current status and future perspectives // Expert. Rev. Cardiovasc. Ther. -
- Vol. 2. - P. 37-51.
Aretz              H.T. Myocarditis: the Dallas criteria // Hum. Pathol. - 1987. - Vol. 18. - P. 619-624.
Pauschinger              M., Doerner A., Kuehl U. et al. Enteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis // Circulation. - 1999. - Vol. 99. -
P. 889-895.
Kuhl              U., Schultheiss H.P. Treatment of chronic myocarditis with corticosteroids // Eur. Heart J. -
- Vol. 16. - P. 168-172.
253.Staudt A., Schaper F., Stangl V. et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution // Circulation. -
- Vol. 103. - P. 2681-2686.
Lip G.Y., Felmeden D.C., Hee F.L. et al. Hypertensive heart disease. A complex syndrome or a hypertensive "cardiomyopathy"? // Eur. Heart J. - 2000. - Vol. 21. - P. 1653-1665.
Pardo Mindan F.J., Panizo A. Alterations in the extracellular matrix of the myocardium in essential hypertension // Eur. Heart J. - 1993. - Vol. 14. - P. 12-14.
256.Schwartzkopff B., Motz W., Frenzel H. et al. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension // Circulation. - 1993. - Vol. 88. - P. 993-1003.
Wolk              R. Arrhythmogenic mechanisms in left ventricular hyper-tro-phy // Europace. - 2000. - Vol. 2. - P. 216-223.
Carlberg              B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? // Lancet. -
- Vol. 364. - P. 1684-1689.
Piano              M.R. Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology // Chest. - 2002. - Vol. 121. - P. 1638-1650.
Kajander              O.A., Kupari M., Laippala P. et al. Dose dependent but non-linear effects of alcohol on the left and right ventricle // Heart. - 2001. - Vol. 86. - P. 417-423.
Urbano-Marquez              A., Estruch R., Fernandez-Sola J. et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men // JAMA. - 1995. - Vol. 274. - P. 149-154.
Fauchier              L. Alcoholic cardiomyopathy and ventricular arrhythmias // Chest. - 2003. - Vol. 123. - 1320 p.
Gavazzi              A., Maria R., Parolini M. et al. Alcohol abuse and dilated cardiomyopathy in men // Am. J. Cardiol. - 2000. - Vol. 85. - P. 1114-1118.
Nicolas              J.M., Fernandez-Sola J., Estruch R. et al. The effect of controlled drinking in alcoholic cardiomyopathy // Ann. Intern. Med. - 2002. - Vol. 136. - P. 192-200.
Bell              D.S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes // Diabetes Care. - 2003. - Vol. 26. - P. 2433-2441.
Avogaro              A., Vigili de Kreutzenberg S., Negut C. et al. Diabetic cardiomyopathy: a metabolic perspective // Am. J. Cardiol. - 2004. - Vol. 93. - P. 13-16.
267.Sen-Chowdhry S., Prasad S., Syrris P. et al. Cardiovascular Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy Revisited // JACC. - 2006. - Vol. 48. - P. 2132-2140.
Eshtehardi              P., Koestner S., Adorjan P. et al. Transient apical ballooning syndrome - clinical characteristics, ballooning pattern, and long-term follow-up in a Swiss population // Int. J. Cardiol. - 2009. - Vol. 135. - P. 370-375.
Koeth              O., Mark B., Kilkowski A. et al. Clinical, angiographic and cardiovascular magnetic resonance findings in consecutive patie